• 1
    Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330:16391644.
  • 2
    Stankovic Stojanovic K, Lionnet F, Girot R, et al. The risk of going abroad in sickle cell disease: a study of 148 adults. Trans R Soc Trop Med Hyg 2011; 105:310314.
  • 3
    Makani J, Williams TN, Marsh K. Sickle cell disease in Africa: burden and research priorities. Ann Trop Med Parasitol 2007; 101:314.
  • 4
    Aygun B, Odame I. A global perspective on sickle cell disease. Pediatr Blood Cancer 2012; 59:386390.
  • 5
    Weatherall D, Akinyanju O, Fuchareon S. Inherited disorders of hemoglobin. In: Jamison DT, ed. Disease control priorities in developing countries. 2nd Ed. Washington: Oxford University Press, World Bank, 2006.
  • 6
    Brandow AM, Panepinto JA. Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease. Am J Hematol 2011; 86:804806.
  • 7
    Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 1999; 94:15501554.
  • 8
    Nzouakou R, Bachir D, Lavaud A, et al. Clinical follow-up of hydroxyurea-treated adults with sickle cell disease. Acta Haematol 2011; 125:145152.
  • 9
    Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 2011; 377:16631672.
  • 10
    National Heart Lung and Blood Institute. Division of Blood Diseases and Resources. The management of sickle cell disease. 4th Ed. Bethesda: National Heart Lung and Blood Institute, 2002.
  • 11
    Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:17371746.
  • 12
    Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 1986; 314:15931599.
  • 13
    Falletta JM, Woods GM, Verter JI, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. J Pediatr 1995; 127:685690.
  • 14
    McCavit TL, Gilbert M, Buchanan GR. Prophylactic penicillin after 5 years of age in patients with sickle cell disease: a survey of sickle cell disease experts. Pediatr Blood Cancer 2013; 60:935939.
  • 15
    McCavit TL. Sickle cell disease. Pediatr Rev 2012; 33:195204.
  • 16
    Sommet J, Missud F, Holvoet L, et al. Morbidity among child travellers with sickle-cell disease visiting tropical areas: an observational study in a French tertiary care centre. Arch Dis Child 2013; 98:533536.
  • 17
    Runel-Belliard C, Lesprit E, Quinet B, Grimprel E. Sickle cell children traveling abroad: primary risk is infection. J Travel Med 2009; 16:253257.
  • 18
    Battersby AJ, Knox-Macaulay HH, Carrol ED. Susceptibility to invasive bacterial infections in children with sickle cell disease. Pediatr Blood Cancer 2010; 55:401406.
  • 19
    Akuse RM. Variation in the pattern of bacterial infection in patients with sickle cell disease requiring admission. J Trop Pediatr 1996; 42:318323.
  • 20
    Kizito ME, Mworozi E, Ndugwa C, Serjeant GR. Bacteraemia in homozygous sickle cell disease in Africa: is pneumococcal prophylaxis justified? Arch Dis Child 2007; 92:2123.
  • 21
    Aken'ova YA, Bakare RA, Okunade MA. Septicaemia in sickle cell anaemia patients: the Ibadan experience. Cent Afr J Med 1998; 44:102104.
  • 22
    Akinyanju O, Johnson AO. Acute illness in Nigerian children with sickle cell anaemia. Ann Trop Paediatr 1987; 7:181186.
  • 23
    Williams TN, Uyoga S, Macharia A, et al. Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case–control study. Lancet 2009; 374:13641370.
  • 24
    Allison AC. Protection afforded by sickle-cell trait against subtertian malareal infection. Br Med J 1954; 1:290294.
  • 25
    Williams TN, Mwangi TW, Wambua S, et al. Sickle cell trait and the risk of Plasmodium falciparum malaria and other childhood diseases. J Infect Dis 2005; 192:178186.
  • 26
    Ambe JP, Fatunde JO, Sodeinde OO. Associated morbidities in children with sickle-cell anaemia presenting with severe anaemia in a malarious area. Trop Doct 2001; 31:2627.
  • 27
    Ibidapo MO, Akinyanju OO. Acute sickle cell syndromes in Nigerian adults. Clin Lab Haematol 2000; 22:151155.
  • 28
    Aluoch JR. Higher resistance to Plasmodium falciparum infection in patients with homozygous sickle cell disease in western Kenya. Trop Med Int Health 1997; 2:568571.
  • 29
    Awotua-Efebo O, Alikor EA, Nkanginieme KE. Malaria parasite density and splenic status by ultrasonography in stable sickle-cell anaemia (HbSS) children. Niger J Med 2004; 13:4043.
  • 30
    Okuonghae HO, Nwankwo MU, Offor E. Malarial parasitaemia in febrile children with sickle cell anaemia. J Trop Pediatr 1992; 38:8385.
  • 31
    Aidoo M, Terlouw DJ, Kolczak MS, et al. Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet 2002; 359:13111312.
  • 32
    Glikman D, Nguyen-Dinh P, Roberts JM, et al. Clinical malaria and sickle cell disease among multiple family members in Chicago, Illinois. Pediatrics 2007; 120:e745e748.
  • 33
    Evans HE, Sampath AC, Douglass F, Baki A. Shigella bacteremia in a patient with sickle cell anemia. Am J Dis Child 1972; 123:238239.
  • 34
    Mahdi NK, Ali NH. Intestinal parasites, including Cryptosporidium species, in Iraqi patients with sickle-cell anaemia. East Mediterr Health J 2002; 8(2–3):345349.
  • 35
    Cook JA, Kellermeyer WF Jr Warren KS, Kellermeyer RW. Sickle cell haemoglobinopathy and Schistosoma mansoni infection. Ann Trop Med Parasitol 1972; 66:197202.
  • 36
    Moesker FM, Muskiet FD, Koeijers JJ, et al. Fatal dengue in patients with sickle cell disease or sickle cell anemia in Curacao: two case reports. PLoS Negl Trop Dis 2013; 7:e2203.
  • 37
    Limonta D, Gonzalez D, Capo V, et al. Fatal severe dengue and cell death in sickle cell disease during the 2001–2002 Havana dengue epidemic. Int J Infect Dis 2009; 13:e77e78.
  • 38
    Bravo JR, Guzman MG, Kouri GP. Why dengue haemorrhagic fever in Cuba? 1. Individual risk factors for dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS). Trans R Soc Trop Med Hyg 1987; 81:816820.
  • 39
    Lionnet F, Bachmeyer C, Sloma I, et al. Tuberculosis in adult patients with sickle cell disease. J Infect 2007; 55:439444.
  • 40
    Nuorti JP, Whitney CG, Centers for Disease Control and Prevention. Prevention of pneumococcal disease among infants and children—use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59(RR-11):118.
  • 41
    Group AAIW, Bridges CB, Woods L, Coyne-Beasley T, Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older—United States, 2013. MMWR Surveill Summ 2013; 62(Suppl 1):919.
  • 42
    Group ACAIW, Akinsanya-Beysolow I, Jenkins R, Meissner HC, Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for persons aged 0 through 18 years—United States, 2013. MMWR Surveill Summ 2013; 62(Suppl 1):28.
  • 43
    Bundy DG, Strouse JJ, Casella JF, Miller MR. Burden of influenza-related hospitalizations among children with sickle cell disease. Pediatrics 2010; 125:234243.
  • 44
    Scheinman JI. Sickle cell disease and the kidney. Nat Clin Pract Nephrol 2009; 5:7888.
  • 45
    da Silva GB Jr, Liborio AB, Daher Ede F. New insights on pathophysiology, clinical manifestations, diagnosis, and treatment of sickle cell nephropathy. Ann Hematol 2011; 90:13711379.
  • 46
    Centers for Disease Control and Prevention. CDC health information for international travel. New York: Oxford University Press, 2012: 470472.
  • 47
    Gomi H, Jiang ZD, Adachi JA, et al. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions. Antimicrob Agents Chemother 2001; 45:212216.
  • 48
    Adachi JA, Ostrosky-Zeichner L, DuPont HL, Ericsson CD. Empirical antimicrobial therapy for traveler's diarrhea. Clin Infect Dis 2000; 31:10791083.
  • 49
    Claster S, Godwin MJ, Embury SH. Risk of altitude exposure in sickle cell disease. West J Med 1981; 135:364367.
  • 50
    Philbrick JT, Shumate R, Siadaty MS, Becker DM. Air travel and venous thromboembolism: a systematic review. J Gen Intern Med 2007; 22:107114.
  • 51
    Stein PD, Beemath A, Meyers FA, et al. Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease. Am J Med 2006; 119:897 e7897 e11.
  • 52
    Naik RP, Streiff MB, Lanzkron S. Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know. J Thromb Thrombolysis 2013; 35:352358.
  • 53
    Field SP, Allain JP. Transfusion in sub-Saharan Africa: does a Western model fit? J Clin Pathol 2007; 60:10731075.
  • 54
    Hansasuta P, Rowland-Jones SL. HIV-1 transmission and acute HIV-1 infection. Br Med Bull 2001; 58:109127.
  • 55
    Lara AM, Kandulu J, Chisuwo L, et al. Laboratory costs of a hospital-based blood transfusion service in Malawi. J Clin Pathol 2007; 60:11171120.
  • 56
    Transportation Security Administration. Medically necessary liquids: travelers with disabilities and medical conditions. Available at: (Accessed 2013 Nov 23).
  • 57
    Murano T, Fox AD, Anjaria D. Acute splenic syndrome in an African-American male with sickle cell trait on a commercial airplane flight. J Emerg Med 2013; 45:e161e165.
  • 58
    Nadesan K, Nagaratnam M. Sudden death during long distance air travel in an Hb S/C disease patient. J Clin Forensic Med 2001; 8:151155.
  • 59
    Ware M, Tyghter D, Staniforth S, Serjeant G. Airline travel in sickle cell disease. Lancet 2008; 352:652.